Top Suppliers:I want be here
  • BioBioPha
  • China
  • Product Name: Atractylenolide I
  • Price: ￥Inquiry/20mg
  • Purity: 98.0%
  • Stocking Period: 1 Day
  • Contact: Xueping-Zheng
Related CAS#:
73069-13-3 474-87-3
147396-00-7 73069-14-4
73030-71-4 412960-54-4
1346174-23-9 50939-54-3
160219-88-5 56297-92-8

73069-13-3

73069-13-3 structure
73069-13-3 structure
  • Name: Atractylenolide I
  • Chemical Name: Atractylenolide I
  • CAS Number: 73069-13-3
  • Molecular Formula: C15H18O2
  • Molecular Weight: 230.302
  • Catalog: Natural product Moss
  • Create Date: 2018-04-18 08:00:00
  • Modify Date: 2024-01-02 13:45:23
  • Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.
Name Atractylenolide I
Synonyms Naphtho[2,3-b]furan-2(4H)-one, 4a,5,6,7,8,8a-hexahydro-3,8a-dimethyl-5-methylene-, (4aS,8aS)-
(4aS,8aS)-3,8a-Dimethyl-5-methylene-4a,5,6,7,8,8a-hexahydronaphtho[2,3-b]furan-2(4H)-one
Atractylenolide-1
Description Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.
Related Catalog
Target

JAK2, STAT3[1], TLR4[4]
In Vitro Atractylenolide I (40, 60, 80, 100, 120, 150 μM) dose- and time-dependently reduces the cell viability in human A375 melanoma cells after treatment for 24, 48 and 72 hours. Atractylenolide I (50 and 100 μM) induces apoptosis of A375 cells in a dose-dependent manner at 48 h of treatment. Atractylenolide I (100 μM) significantly reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, without effect on total JAK2 and STAT3. Furthermore, Atractylenolide I inhibits the mRNA expression of STAT3-targeted genes, including Bcl-xL, MMP-2 and MMP-9[1]. Atractylenolide I (up to 100 μM) shows no toxicity in normal cells. Atractylenolide I (25, 50 μM) decreases the Ox-LDL induced TNF-α, IL-6 and NO production in VSMCs. Atractylenolide I (12.5, 25 or 50 μM) significantly reduces the level of MCP-1 and inhibits Ox-LDL-induced VSMCs proliferation and migration. Atractylenolide I (25, 50 μM) inhibits positive staining of foam cells, and also significantly decreases lipid accumulation. Atractylenolide I (50 μM) suppresses p38MAPK and NF-κB p65 expression in VSMCs stimulated by Ox-LDL[3]. Atractylenolide I (1, 10, 100 μM) downregulates paclitaxel-induced expression of VEGF and survivin via MyD88-dependent TLR4 signaling in EOC cells[4].
In Vivo Atractylenolide I (5, 10 or 20 mg/kg, p.o.) restores the decreased body weight in mice subjected to chronic unpredictable mild stress (CUMS). Atractylenolide I alleviates CUMS-induced depressive-like behavior, attenuates CUMS-induced imbalances in hippocampal neurotransmitter levels and reduces CUMS-induced increases in hippocampal pro-inflammatory cytokine levels and in the NLRP3 inflammasome in the hippocampi of mice[2].
Cell Assay Briefly, serum starved VSMCs are pre-treated with indicated concentration of Atractylenolide I for 1 h followed by stimulation with Ox-LDL for 24 h. The purple formazan crystals formed after addition of MTT are solubilized in DMSO and absorbance is measured at 540 nm. The viability or proliferation rate is calculated as percentage of control (untreated VSMCs)[3].
Animal Admin Mice[2] After adaption for one week, 48 male ICR mice are randomly divided into six groups (eight mice per group): Control group (unstressed + saline vehicle), model group (CUMS + saline vehicle), three Atractylenolide I treatment groups (CUMS + Atractylenolide I) and a fluoxetine group (CUMS + FLU). From the 4th week, Atractylenolide I (5, 10 or 20 mg/kg) or fluoxetine (20 mg/kg) is daily administered by oral gavage for 3 weeks. After the last administration of Atractylenolide I or fluoxetine, behavioral tests are performed[2].
References

[1]. Atractylenolide I, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I. Exp Dermatol. 2018 Feb;27(2):201-204.

[2]. Gao H, et al. Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018 Feb;15(2):1574-1579.

[3]. Li W, et al. Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation, migration and inflammatory responses in vitro. Exp Cell Res. 2017 Apr 1;353(1):26-34.

[4]. Huang JM, et al. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014 Jan 23;4:3840.
Density 1.1±0.1 g/cm3
Boiling Point 405.0±44.0 °C at 760 mmHg
Melting Point 121-123 °C
Molecular Formula C15H18O2
Molecular Weight 230.302
Flash Point 170.8±25.9 °C
Exact Mass 230.130676
PSA 26.30000
LogP 3.77
Vapour Pressure 0.0±0.9 mmHg at 25°C
Index of Refraction 1.555
Storage condition 2-8°C
Water Solubility methanol: soluble1mg/mL, clear, colorless
Hazard Codes Xi
RIDADR NONH for all modes of transport

Chemsrc provides CAS#:73069-13-3 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 73069-13-3 | Chemsrc address: https://www.chemsrc.com/en/baike/951862.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved